Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure

Am J Hematol. 2023 Oct;98(10):E281-E284. doi: 10.1002/ajh.27043. Epub 2023 Jul 29.

Authors

Samuel Urrutia¹, Kelly S Chien², Ziyi Li³, Alex Bataller², Emmanuel Almanza², Koji Sasaki², Guillermo Montalban-Bravo², Nicholas J Short², Elias Jabbour², Tapan M Kadia², Farhad Ravandi², Gautam Borthakur², Yesid Alvarado², Naval Daver², Rashmi Kanagal-Shamanna⁴, Carlos Bueso-Ramos⁴, Sherry A Pierce², Hagop Kantarjian², Guillermo Garcia-Manero²

Affiliations

¹ Division of Cancer Medicine, MD Anderson Cancer Center, Houston, Texas, USA.
² Department of Leukemia, MD Anderson Cancer Center, Houston, Texas, USA.
³ Department of Biostatistics, MD Anderson Cancer Center, Houston, Texas, USA.
⁴ Department of Hematopathology, MD Anderson Cancer Center, Houston, Texas, USA.

PMID: 37515433
DOI: 10.1002/ajh.27043

Abstract

Evaluation of IPSS-M and exploratory prognostic model for MDS at the time of HMA failure.

© 2023 Wiley Periodicals LLC.

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

Humans
Myelodysplastic Syndromes* / drug therapy
Prognosis